Antitumor agent-23

Antitumor agent-23 is a potent anti-cancer agent with GI50s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Antitumor agent-23 (0.001-100 μM; 5 days) inhibits lymphoma cells proliferation[1]. Antitumor agent-23 (2-70 nM; 72 hours) induces p53 protein expression and p53 lysine 382 acetylation (K382Ac-p53) in HPV-positive cervical cancer cell[1]. Cell Proliferation Assay[1] Cell Line: Lymphoma cell line GRANTA-519, KARPAS-422,KARPAS-299, RAMOS, DAUDI, RAJI Concentration: 0.001, 0.01, 0.1, 1, 10, 100 μM Incubation Time: 5 days Result: The GI50s of 38, 48, 5, 27, 80, 28 nM for GRANTA-519, KARPAS-422,KARPAS-299, RAMOS, DAUDI, RAJI cells, respectively. Western Blot Analysis[1] Cell Line: HPV16-positive cervical cancer cell line (CaSki cell) Concentration: 2, 7, 20, and 70 nM Incubation Time: 72 hours Result: Induction of p53 protein above baseline was evident at 7 nM already, acetylation of p53 lysine 382 was detectable at 20 nM.

[1]. Marc Labelle, et al. 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer. WO2019118973A1.